Celularity Inc (CELU)

$1.33 +0.02 (1.53%)
Market Cap 37.78M
Revenue (ttm) 54.22M
Net Income (ttm) -57.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -106.77%
Debt to Equity Ratio -1.99
Volume 12,900
Avg Vol 184,792
Day's Range N/A - N/A
Shares Out 28.84M
Stochastic %K 100%
Beta 0.70
Analysts Sell
Price Target $6.00

Company Profile

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degene...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 768 2170
Address:
170 Park Avenue, Florham Park, United States
GODofPoor
GODofPoor Apr. 2 at 7:30 PM
$CELU 🫡
0 · Reply
Nosay
Nosay Apr. 1 at 4:47 PM
$CELU market reacts with a meh🤷‍♂️ 3k shares traded and down 1%. Was it already baked in?
1 · Reply
CharlieMungersghost
CharlieMungersghost Apr. 1 at 9:50 AM
$CELU I think this was obvious from cfo change. Who knows what hariri thinks. Not normal.
1 · Reply
KingStocks1
KingStocks1 Mar. 31 at 11:53 PM
$CELU these guys will file bankruptcy. I’m so pissed i wasted my money on Hariri
0 · Reply
Nosay
Nosay Mar. 30 at 7:47 PM
$CELU wisdom man on Reddit has indicated we’re getting the 10k this week. He’s always denied it but I suspect he is an employee of the company. He seems to catch absolutely everything about the company and doesn’t post about anything else. I’m feeling much better that they’ll atleast be released on time.
0 · Reply
mf3rs
mf3rs Mar. 30 at 12:37 PM
$CELU I was wrong. It's 60 days from commencement date of the deal. Section 4.1 https://s3.amazonaws.com/sec.irpass.cc/2739/0001493152-26-009471.pdf
1 · Reply
mf3rs
mf3rs Mar. 30 at 11:32 AM
$CELU 2 days to file the 10k or miss out on the 20 mil. Will it be filed on time?
1 · Reply
Nosay
Nosay Mar. 26 at 12:16 PM
$CELU look at the 1 year chart. Last July this had 7m in volume and good premarket gains a week or so before a good run before dwindling back. We had almost the exact same volume the other day (7m) and we have some great catalysts on the horizon. Interestingly most shorts have closed their positions as of late February. By April 15th I think this is $5
0 · Reply
Coux
Coux Mar. 23 at 5:03 PM
$CELU i do hope their will be a decent pr with guidance what to expect because their lacking skills in that deparment followed by a 10k this week or on monday… milestones i dont think their will be from biocell yet, maybe in Q1 …more explantion About nexgel agreement…
0 · Reply
Nosay
Nosay Mar. 21 at 10:45 AM
$CELU Joe Rogan’s recent episode with Brigham Buehler goes into stem cell use a lot. Hopefully it gets people excited about the possibilities and potential as well as different level of governments to follow in Florida, Utah, Wyoming, and soon to be Arizonas foot steps. I was definitely a year and a half a half early in this thing. Management has definitely been way too quiet and somewhat confusing with their strategy. But I still see the potential here for a 10x type run in the very near future.
0 · Reply
Latest News on CELU
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Mar 12, 2026, 8:30 AM EDT - 21 days ago

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue

Mar 10, 2026, 8:30 AM EDT - 23 days ago

EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue

NXGL

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Mar 10, 2026, 8:30 AM EDT - 23 days ago

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

Feb 10, 2026, 8:30 AM EST - 7 weeks ago

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

Dec 26, 2025, 8:30 AM EST - 3 months ago

Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

Celularity Announces Closing of Financing Transactions

Dec 22, 2025, 4:01 PM EST - 3 months ago

Celularity Announces Closing of Financing Transactions

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

Dec 18, 2025, 2:10 PM EST - 3 months ago

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

Oct 30, 2025, 8:00 AM EDT - 5 months ago

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

Oct 14, 2025, 8:45 AM EDT - 6 months ago

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Sep 3, 2025, 8:00 AM EDT - 7 months ago

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Aug 22, 2025, 5:30 PM EDT - 7 months ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

Aug 18, 2025, 8:00 AM EDT - 8 months ago

Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

Jul 9, 2025, 8:30 AM EDT - 9 months ago

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

Jul 1, 2025, 8:30 AM EDT - 9 months ago

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

Celularity Announces Chief Financial Officer Transition

Jun 10, 2025, 4:15 PM EDT - 10 months ago

Celularity Announces Chief Financial Officer Transition

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

Jun 2, 2025, 8:00 AM EDT - 10 months ago

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

Celularity Announces Full Year 2024 Operating and Financial Results

May 9, 2025, 9:15 AM EDT - 11 months ago

Celularity Announces Full Year 2024 Operating and Financial Results

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Apr 25, 2025, 5:30 PM EDT - 1 year ago

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Feb 25, 2025, 8:00 AM EST - 1 year ago

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Feb 24, 2025, 8:00 AM EST - 1 year ago

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Dec 10, 2024, 8:00 AM EST - 1 year ago

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Dec 6, 2024, 8:00 AM EST - 1 year ago

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Celularity Inc. Announces Receipt of Nasdaq Notification

Nov 27, 2024, 5:00 PM EST - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notification

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Nov 20, 2024, 8:30 AM EST - 1 year ago

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Oct 18, 2024, 6:00 PM EDT - 1 year ago

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Oct 16, 2024, 5:15 PM EDT - 1 year ago

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Appoints Richard J. Berman to its Board of Directors

Aug 28, 2024, 4:45 PM EDT - 1 year ago

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Aug 23, 2024, 5:00 PM EDT - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 3, 2024, 8:38 AM EDT - 1 year ago

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

May 14, 2024, 9:15 AM EDT - 2 years ago

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Celularity Inc. to Host Investor and Analyst Research & Development Day

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Celularity Inc. to Host Investor and Analyst Research & Development Day

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 19, 2024, 5:30 PM EDT - 2 years ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Apr 18, 2024, 4:30 PM EDT - 2 years ago

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Apr 8, 2024, 9:00 AM EDT - 2 years ago

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Mar 26, 2024, 9:00 AM EDT - 2 years ago

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Mar 20, 2024, 9:15 AM EDT - 2 years ago

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Mar 14, 2024, 9:15 AM EDT - 2 years ago

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Mar 12, 2024, 9:20 AM EDT - 2 years ago

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Mar 7, 2024, 9:35 AM EST - 2 years ago

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Celularity Announces 1-for-10 Reverse Stock Split

Feb 23, 2024, 4:10 PM EST - 2 years ago

Celularity Announces 1-for-10 Reverse Stock Split

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Feb 14, 2024, 4:05 PM EST - 2 years ago

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Feb 1, 2024, 9:00 AM EST - 2 years ago

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

Jan 25, 2024, 9:00 AM EST - 2 years ago

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

Celularity Releases CEO Letter to Shareholders

Jan 18, 2024, 1:40 PM EST - 2 years ago

Celularity Releases CEO Letter to Shareholders

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

Jan 4, 2024, 1:00 PM EST - 2 years ago

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

GODofPoor
GODofPoor Apr. 2 at 7:30 PM
$CELU 🫡
0 · Reply
Nosay
Nosay Apr. 1 at 4:47 PM
$CELU market reacts with a meh🤷‍♂️ 3k shares traded and down 1%. Was it already baked in?
1 · Reply
CharlieMungersghost
CharlieMungersghost Apr. 1 at 9:50 AM
$CELU I think this was obvious from cfo change. Who knows what hariri thinks. Not normal.
1 · Reply
KingStocks1
KingStocks1 Mar. 31 at 11:53 PM
$CELU these guys will file bankruptcy. I’m so pissed i wasted my money on Hariri
0 · Reply
Nosay
Nosay Mar. 30 at 7:47 PM
$CELU wisdom man on Reddit has indicated we’re getting the 10k this week. He’s always denied it but I suspect he is an employee of the company. He seems to catch absolutely everything about the company and doesn’t post about anything else. I’m feeling much better that they’ll atleast be released on time.
0 · Reply
mf3rs
mf3rs Mar. 30 at 12:37 PM
$CELU I was wrong. It's 60 days from commencement date of the deal. Section 4.1 https://s3.amazonaws.com/sec.irpass.cc/2739/0001493152-26-009471.pdf
1 · Reply
mf3rs
mf3rs Mar. 30 at 11:32 AM
$CELU 2 days to file the 10k or miss out on the 20 mil. Will it be filed on time?
1 · Reply
Nosay
Nosay Mar. 26 at 12:16 PM
$CELU look at the 1 year chart. Last July this had 7m in volume and good premarket gains a week or so before a good run before dwindling back. We had almost the exact same volume the other day (7m) and we have some great catalysts on the horizon. Interestingly most shorts have closed their positions as of late February. By April 15th I think this is $5
0 · Reply
Coux
Coux Mar. 23 at 5:03 PM
$CELU i do hope their will be a decent pr with guidance what to expect because their lacking skills in that deparment followed by a 10k this week or on monday… milestones i dont think their will be from biocell yet, maybe in Q1 …more explantion About nexgel agreement…
0 · Reply
Nosay
Nosay Mar. 21 at 10:45 AM
$CELU Joe Rogan’s recent episode with Brigham Buehler goes into stem cell use a lot. Hopefully it gets people excited about the possibilities and potential as well as different level of governments to follow in Florida, Utah, Wyoming, and soon to be Arizonas foot steps. I was definitely a year and a half a half early in this thing. Management has definitely been way too quiet and somewhat confusing with their strategy. But I still see the potential here for a 10x type run in the very near future.
0 · Reply
luckydog2
luckydog2 Mar. 16 at 7:58 PM
$CELU The therapeutic potential of natural killer (NK) cells to combat aging and age-related diseases https://www.reddit.com/r/CelularityNews/s/y5wUVzlGdx
0 · Reply
silentmaxx
silentmaxx Mar. 13 at 4:10 PM
$CELU
0 · Reply
luckydog2
luckydog2 Mar. 12 at 1:39 PM
$CELU Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities https://www.globenewswire.com/news-release/2026/03/12/3254647/0/en/Celularity-Reiterates-Strategic-Commercialization-Partnership-with-NEXGEL-Focused-on-Building-Biomaterials-Franchise-with-Established-Commercial-Products-and-New-510-k-Pathway-Prod.html
2 · Reply
silentsparrow
silentsparrow Mar. 11 at 7:02 PM
$AMFN Tried to tell you. We still have 94 cents left to go. Dont miss out kids $BTCM $CELU $OPTT $JDZG
0 · Reply
luckydog2
luckydog2 Mar. 11 at 4:26 PM
$CELU
0 · Reply
GODofPoor
GODofPoor Mar. 11 at 3:41 PM
$CELU just bought some 🤞
0 · Reply
ERQ
ERQ Mar. 11 at 11:57 AM
$CELU Honestly I am more excited about this stock now than ever. They kept their manufacturing . They got cash and are now doing what they set out to do in the first place. The placental derived longevity therapy has always been Dr. Harri’s core focus. This is the future of medicine.
1 · Reply
Jeffartist
Jeffartist Mar. 11 at 9:55 AM
$AMFN $BTCM $CELU $OPTT $JDZG
0 · Reply
silentsparrow
silentsparrow Mar. 11 at 1:23 AM
$AMFN the 2 most bullish pictures i own! Worlds very 1st working fusion reactor! And the my main main Dr. B SAYING we have a live demo coming our way!!! Plenty of dd on our page! Not asking you to buy a milly shares. Just do some dd $BTCM $CELU $OPTT $JDZG
0 · Reply
luckydog2
luckydog2 Mar. 11 at 12:25 AM
$CELU
1 · Reply
Sacsofcash
Sacsofcash Mar. 11 at 12:22 AM
$CELU 1.3900 0.0000 (0.00%) Overnight: 8:00:25 PM EDT
0 · Reply
focafoca99
focafoca99 Mar. 10 at 8:31 PM
$CELU is on the other side of that NexGel transaction, selling assets while entering an exclusive license setup
0 · Reply